144
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Impact of Smoking on COVID-19 Symptoms in Non-Vaccinated Patients: A Matched Observational Study from Qatar

ORCID Icon, , , , , , , , ORCID Icon, , , , , , , & ORCID Icon show all
Pages 531-540 | Published online: 17 Mar 2022

References

  • Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New Engl J Med. 2020;382(16):1564–1567. doi:10.1056/NEJMc2004973
  • Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). In: Statpearls [Internet]. StatPearls Publishing; 2020.
  • Wang Y, Wang Y, Chen Y, Qin QJ. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J Med Virol. 2020;92(6):568–576. doi:10.1002/jmv.25748
  • Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020;9(3):841. doi:10.3390/jcm9030841
  • Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar AJC. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. doi:10.7759/cureus.7355
  • Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health. 2018;15(5):1033. doi:10.3390/ijerph15051033
  • Bagaitkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis. 2008;4(1):12. doi:10.1186/1617-9625-4-12
  • Zambon JJ, Grossi SG, Machtei EE, Ho AW, Dunford R, Genco RJ. Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. J Periodontol. 1996;67(10 Suppl):1050–1054. doi:10.1902/jop.1996.67.10s.1050
  • Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–2216. doi:10.1001/archinte.164.20.2206
  • Eapen MS, Sharma P, Moodley YP, Hansbro PM, Sohal SS. Dysfunctional immunity and microbial adhesion molecules in smoking-induced pneumonia. Am J Respir Crit Care Med. 2019;199(2):250–251. doi:10.1164/rccm.201808-1553LE
  • Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, de Granda-orive JI. COVID-19 and smoking: a systematic review and meta-analysis of the evidence. Arch Bronconeumol. 2021;57 Suppl 1:21–34. doi:10.1016/j.arbres.2020.06.024
  • Han L, Ran J, Mak Y-W, et al. Smoking and influenza-associated morbidity and mortality: a systematic review and meta-analysis. Epidemiology. 2019;30(3):405–417. doi:10.1097/EDE.0000000000000984
  • Lawrence H, Hunter A, Murray R, Lim W, McKeever T. Cigarette smoking and the occurrence of influenza–systematic review. J Infect. 2019;79(5):401–406. doi:10.1016/j.jinf.2019.08.014
  • Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15(5):e0233147. doi:10.1371/journal.pone.0233147
  • Zhang -J-J, Dong X, Cao -Y-Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730–1741. doi:10.1111/all.14238
  • Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
  • Smith JC, Sausville EL, Girish V, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. 2020;53(5):514–529.e513. doi:10.1016/j.devcel.2020.05.012
  • Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20. doi:10.18332/tid/119324
  • Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2021;116(6):1319–1368. doi:10.1111/add.15276
  • Farsalinos K, Angelopoulou A, Alexandris N, Poulas K. COVID-19 and the nicotinic cholinergic system. Eur Respir J. 2020;56(1):2001589. doi:10.1183/13993003.01589-2020
  • Leung JM, Sin DD. Smoking, ACE-2, and COVID-19: ongoing controversies. Eur Respir J. 2020;56:2001759. doi:10.1183/13993003.01759-2020
  • Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032–1038. doi:10.1097/cm9.0000000000000775
  • Chen X, Tong J, Xiang J, Hu J. Retrospective study on the epidemiological characteristics of 139 patients with novel coronavirus pneumonia on the effects of severity. Chongqing Med. 2020;3:1–9.
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5
  • Killerby ME, Link-Gelles R, Haight SC, et al. Characteristics associated with hospitalization among patients with COVID-19 — metropolitan Atlanta, Georgia, March–April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):790–794. doi:10.15585/mmwr.mm6925e1
  • Karanasos A, Aznaouridis K, Latsios G, et al. Impact of smoking status on disease severity and mortality of hospitalized patients with COVID-19 infection: a systematic review and meta-analysis. Nicotine Tob Res. 2020;22(9):1657–1659. doi:10.1093/ntr/ntaa107
  • Zhang H, Ma S, Han T, et al. Association of smoking history with severe and critical outcomes in COVID-19 patients: a systemic review and meta-analysis. Eur J Integr Med. 2021;43:101313. doi:10.1016/j.eujim.2021.101313
  • Omar SM, Musa IR, Salah SE, Elnur MM, Al-Wutayd O, Adam I. High mortality rate in adult COVID-19 inpatients in Eastern Sudan: a Retrospective Study. J Multidiscip Healthc. 2020;13:1887–1893. doi:10.2147/jmdh.S283900
  • Shaikh F, Aldhafferi N, Buker A, et al. Comorbidities and risk factors for severe outcomes in COVID-19 patients in Saudi Arabia: a Retrospective Cohort Study. J Multidiscip Healthc. 2021;14:2169–2183. doi:10.2147/JMDH.S317884
  • Al Kuwari HM, Abdul Rahim HF, Abu-Raddad LJ, et al. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020. BMJ Open. 2020;10(10):e040428. doi:10.1136/bmjopen-2020-040428
  • Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. doi:10.1136/bmj.m1996
  • Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380–1388. doi:10.1164/rccm.202002-0445OC
  • Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–e18. doi:10.1016/j.jinf.2020.03.005
  • Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study. J Infect Public Health. 2020;13(7):920–925. doi:10.1016/j.jiph.2020.05.026
  • Alyami MH, Naser AY, Orabi MAA, Alwafi H, Alyami HS. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an Ecological Study. Front Public Health. 2020;8(506). doi:10.3389/fpubh.2020.00506
  • Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience. 2020;42(2):505–514. doi:10.1007/s11357-020-00186-0
  • Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;46(8):1603–1606. doi:10.1007/s00134-020-06088-1
  • AlJishi JM, Alhajjaj AH, Alkhabbaz FL, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. J Infect Public Health. 2021;14(1):6–11. doi:10.1016/j.jiph.2020.11.002
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/s0140-6736(20)30566-3
  • Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei AR. Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis. Arch Bone Jt Surg. 2020;8(Suppl1):247–255. doi:10.22038/abjs.2020.47754.2346
  • Khamis F, Al-Zakwani I, Al Naamani H, et al. Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman. J Infect Public Health. 2020;13(7):906–913. doi:10.1016/j.jiph.2020.06.002
  • Khan A, Althunayyan S, Alsofayan Y, et al. Risk factors associated with worse outcomes in COVID-19: a retrospective study in Saudi Arabia. East Mediterr Health J. 2020;26(11):1371–1380. doi:10.26719/emhj.20.130
  • Abohamr SI, Abazid RM, Aldossari MA, et al. Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia. Saudi Med J. 2020;41(11):1217–1226. doi:10.15537/smj.2020.11.25495
  • Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509–515. doi:10.1161/atvbaha.113.300156
  • Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi:10.1016/j.jinf.2020.04.021
  • Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22(9):1653–1656. doi:10.1093/ntr/ntaa082
  • Almazeedi S, Al-Youha S, Jamal MH, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. EClinicalMedicine. 2020;24:100448. doi:10.1016/j.eclinm.2020.100448
  • Soares RCM, Mattos LR, Raposo LM. Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo State, Brazil. Am J Trop Med Hyg. 2020;103(3):1184–1190. doi:10.4269/ajtmh.20-0483
  • Zhao Z, Chen A, Hou W, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS One. 2020;15(7):e0236618. doi:10.1371/journal.pone.0236618
  • Mohsin FM, Tonmon TT, Nahrin R, et al. Association between smoking and COVID-19 severity: evidence from Bangladesh. J Multidiscip Healthc. 2021;14:1923–1933. doi:10.2147/JMDH.S317603
  • Archie SR, Cucullo L. Cerebrovascular and neurological dysfunction under the threat of COVID-19: is there a comorbid role for smoking and vaping? Int J Mol Sci. 2020;21(11):3916. doi:10.3390/ijms21113916
  • Ujjan ID, Devrajani BR, Ghanghro AA, Shah SZA. The clinical and demographical profile of Coronavirus illness: the tale of Tablighi Jamaat and Zaireen in Quarantine/Isolation center at Sukkur and Hyderabad. Pak J Med Sci. 2020;36(Covid19–s4):S12–s16. doi:10.12669/pjms.36.COVID19-S4.2829
  • Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92(10):1915–1921. doi:10.1002/jmv.25889
  • Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688. doi:10.1183/13993003.00688-2020
  • Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2018;315(5):R895–r906. doi:10.1152/ajpregu.00099.2018
  • Changeux JP, Amoura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. C R Biol. 2020;343(1):33–39. doi:10.5802/crbiol.8
  • Yilin Z, Yandong N, Faguang JJB. Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. Burns. 2015;41(7):1468–1477. doi:10.1016/j.burns.2015.04.010
  • Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–2845. doi:10.1111/all.14429
  • Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi:10.1007/s00392-020-01626-9
  • Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408–1415. doi:10.2337/dc20-0723
  • Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging. 2020;12(11):10087–10098. doi:10.18632/aging.103415
  • Saheb Sharif-Askari N, Saheb Sharif-Askari F, Alabed M, et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol Ther - Methods Clin Dev. 2020;18:1–6. doi:10.1016/j.omtm.2020.05.013
  • Cruz T, López-Giraldo A, Noell G, et al. Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respir Res. 2019;20(1):152. doi:10.1186/s12931-019-1105-z
  • Kim WJ, Lim JH, Lee JS, Lee S-D, Kim JH, Oh Y-M. Comprehensive analysis of transcriptome sequencing data in the lung tissues of COPD subjects. Int J Genomics. 2015;2015:206937. doi:10.1155/2015/206937
  • McDonough JE, Ahangari F, Li Q, et al. Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 2019;4(22):e131597. doi:10.1172/jci.insight.131597
  • Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005;2(9):e251. doi:10.1371/journal.pmed.0020251
  • Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi:10.1016/j.rmed.2020.105941
  • Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
  • Kowitt SD, Cornacchione Ross J, Jarman KL, et al. Tobacco quit intentions and behaviors among cigar smokers in the United States in response to COVID-19. Int J Environ Res Public Health. 2020;17(15):5368. doi:10.3390/ijerph17155368
  • Caponnetto P, Inguscio L, Saitta C, Maglia M, Benfatto F, Polosa R. Smoking behavior and psychological dynamics during COVID-19 social distancing and stay-at-home policies: a survey. Health Psychol Res. 2020;8(1):9124. doi:10.4081/hpr.2020.9124
  • Sun Y, Li Y, Bao Y, et al. Brief report: increased addictive internet and substance use behavior during the COVID-19 pandemic in China. Am J Addict. 2020;29(4):268–270. doi:10.1111/ajad.13066
  • Patwardhan P. COVID-19: risk of increase in smoking rates among England’s 6 million smokers and relapse among England’s 11 million ex-smokers. BJGP Open. 2020;4(2):bjgpopen20X101067. doi:10.3399/bjgpopen20X101067
  • Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2021;93(2):1045–1056. doi:10.1002/jmv.26389
  • Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320935765. doi:10.1177/2040622320935765
  • Smith EW, Smith KA, Maibach HI, Andersson PO, Cleary G, Wilson D. The local side effects of transdermally absorbed nicotine. Skin Pharmacol. 1992;5(2):69–76. doi:10.1159/000211021
  • Berlin I, Thomas D, Le Faou A-L, Cornuz J. COVID-19 and smoking. Nicotine Tob Res. 2020;22(9):1650–1652. doi:10.1093/ntr/ntaa059
  • Alexandris N, Lagoumintzis G, Chasapis CT, et al. Nicotinic cholinergic system and COVID-19: in silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions. Toxicol Rep. 2021;8:73–83. doi:10.1016/j.toxrep.2020.12.013